© 2018 Miraculo Inc. All Rights Reserved
Multiple Sclerosis is a debilitating syndrome that affects millions of people worldwide. It can cause muscle spasticity and chronic pain in humans and it has been proven to be quite hard to treat. Normal medications include pharmaceuticals and rehab, along with counselling to help the MS patient with their symptoms. It has been said that cannabinoids have an anti inflammatory effect on human cells. Cannabinoids are found within the marijuana plant (cannabis sativa) and is reported to be a good go-to for the alleviation of pain symptoms such as multiple sclerosis and it’s related side effects.
Cannabinoids are allowed to work in the body by way of the cannabinoid receptors, 1 and 2, in the endocannabinoid system. Tetrahydrocannabinol (THC) is one of the main constituents of the cannabinoid group and is said to be responsible for the stoned feeling in humans. Cannabidiol (CBD) is another constituent of cannabis and it is said to have a huge neuroprotective potential in humans. This paper will embark on a brief journey into the therapeutic properties of cannabidiol and how these properties can be applied to patients with MS.
This is a huge era for cannabinoid studies. Reports indicate that cannabis (marijuana) can reduce conditions like muscle stiffness and chronic pain in people with multiple sclerosis (MS). Intrigue in the area of cannabinoids has been fortified by the discovery and duplicating of cannabinoid receptors found in the central nervous network and the peripheral immune organs, and by the identification of the endogenous cannabinoids. Cannabinoids are also effective in animal experiments of MS. However, there have been merely ten published clinical evaluations on the application of marijuana in MS, including 78 people around the world and the conclusions have been massive. Scientists have found a numerous amount of hardships in structuring clinical research that apply cannabinoids. From the research looking into the application of cannabinoids in people with MS related muscle stiffness, more efficient structured research was not successful in showing goal improvement. Therefore, authentic reports that cannabinoids are efficient in MS is still not up to scratch.
The complicated nature of the cannabinoid network is coming more into light, involving its plausible detrimental position in mediating synaptic brain signalling, inflammation and brain protection. Reports from people who smoke cannabis gives us reason to believe that cannabinoids have a possible outcome as an MS treatment. There is reason to believe that cannabinoids can allow an anti inflammatory and neuroprotection mechanism into the act of disease modification. There is actually quite little scientific knowledge gathered about cannabinoids ability to cure MS and media reports can be quite deceiving when it comes to over exaggerating this knowledge. Clinical appliance of cannabinoids in MS is still in its larval stages and there is has been many shortcomings when it has come to MS symptom alleviation in patients. However, there was been some people in the past who have said there muscle stiffness had improved with the application of cannabinoids. Future research should take place so that a broader understanding of how cannabinoids can prevent muscle spascity from getting worse can be conjured up.